康柏西普对糖尿病性黄斑水肿的疗效评价

Clinical efficacy of intravitreal injection of Conbercept in treatment of diabetic macular edema

目的·评价玻璃体腔内注射抗血管内皮生长因子(VEGF)药物康柏西普对治疗糖尿病性黄斑水肿(DME)的临床效果。方法·选取DME(炎症型)患者11例17眼,每月行1次康柏西普玻璃体腔内注射,首次治疗之后按需治疗。治疗结束后随诊6个月以上,比较治疗前后患者的最佳矫正视力(BCVA)、中央视网膜厚度(CRT)、DME消退率及眼底荧光血管造影检查(FFA)结果。结果·随访时间为7~29个月,平均(12±7)个月。注射针数1~10针,平均针数为(4±3)针。DME患者注药后BCVA明显提高(t=7.306,P=0.001),CRT下降显著(t=5.272,P=0.000),差异有统计学意义。DME总消退率为76.5%。结论·玻璃体腔内注射抗VEGF药物康柏西普,可明显改善DME患者的视力,明显消退黄斑水肿症状。

Objective·To investigate the clinical effect of intravitreal injection of Conbercept in the treatment of diabetic macular edema(DME).Methods·Eleven patients(17eyes)with DME(inflammatory type)received intravitreal injection of Conbercept monthly.After the first treatment,the patients were treated on demand.Follow-up after treatment for more than6months,the best corrected visual acuity(BCVA),central retinal thickness(CRT),diminished rate of DME and result of fundus fluorescein angiography(FFA)of DME eyes before and after treatment were compared.Results·During a follow-up of7-29months[(12±7)months],the injections were given1-10times[(4±3)times].The results showed that the treatment effects on improving BCVA(logMAR)and diminishing of CRT were significant(t=7.306,P=0.001;t=5.272,P=0.000).The diminished rate of DME of our patients was76.5%.Conclusion·Intravitreal injection of Conbercept in the treatment of DME is effective on reducing macular edema and improving visual acuity.